For the last four decades in early breast cancer overexpressing estrogen receptors, tamoxifen (TAM) has been the standard therapy for nonmenopausal women, as it is able to reduce the risk of recurrence and decrease breast cancer mortality [1]. Here, ESR1 is linked to breast cancer.